Dr. Piekarz is a Medical Officer in the Investigational Therapeutics 3 Section of the Investigational Drug Branch of CTEP. Dr. Piekarz is a graduate of the Albert Einstein College of Medicine, where he received a PhD in Molecular Pharmacology in addition to an MD. He did his internship and residency in Internal Medicine at the University Hospitals of Cleveland. Dr. Piekarz served as a Medical Oncology Fellow and then Senior Fellow at the NCI-Navy Medical Oncology program where he also served as a Staff Clinician prior to joining IDB. He is also a Preceptor at the Uniformed Services University of the Health Sciences (USUHS) Department of Pharmacology. Dr. Piekarz background includes the development of the HDAC inhibitors. This included demonstration of their efficacy in patients with T-cell lymphoma, conduction of a thorough analysis of its cardiac effects, and laboratory work to define their molecular effects and potential mechanisms of resistance.
Dr. Piekarz recently joined IDB and will be assuming responsibilities for fostamatinib (R935788), dimethyl sulfonate, and ixabepilone.
National Cancer Institute
Executive Plaza North, Suite 7131
Rockville MD, 20852-7426